Successfully navigating a drug development cycle is a major undertaking. On average, the sequence takes over a decade to ...

The FDA issued its first stamp of approval for a cell or gene therapy back in 2017 to Novartis' Kymriah. | The gene therapy ...

Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, marked the sixth anniversary since its ...

Baidu CEO’s life sciences startup sees artificial intelligence ... is transforming fields like drug discovery by reducing ...

However, the biotech and pharmaceutical companies that develop these therapies do so at great expense. High drug development ...

A balance must be struck between rapid access to potentially life-saving drugs and the importance of ensuring their safety ...

Trinity Life Sciences, the leader in strategy, insights and analytics for the life sciences industry, delivers life science ...

Bank of America Securities analyst Michael Ryskin reiterated a Buy rating on Stevanato Group (STVN – Research Report) yesterday and set a ...

He believes issues including rising obesity rates and declining life expectancy ... consultants and lobbyists cycle in and out of these agencies,” he said in August before adding: “A sick child is the ...

Quantiphi Global Head of Healthcare and Life Sciences Barinder Marhok said the partnership marries DDReg’s expertise in ...

Stevanato Group Spa ( (STVN) ) has released its Q3 earnings. Here is a breakdown of the information Stevanato Group Spa presented to its ...

STAT gathered reactions from leaders across biotech and pharma about what the new Trump era could mean for them.